Guru Bars

Home ▶ Unknown

Enhance your educational experience during ATS 2022 by joining industry experts in an burst session with engaging discussion on the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine.

convo-icon.svg



Sunday, May 15, 2022

Moscone Center

Guru Bar 1

Explore the Clinical Presentation of Type 2 Inflammation in Oral Corticosteroid-Dependent Asthma

11:30 AM - 11:50 AM


Go beyond the standard didactic presentation and interact with an expert in this open-air presentation on the clinical importance of type 2 inflammation in a case-based review of a hypothetical patient with oral corticosteroid-dependent asthma.

Speaker: Cedric "Jamie" Rutland MD West Coast Lung

Company: Sanofi and Regeneron

Accurate Procedural Mapping with Peripheral Navigation

12:30 PM - 12:50 PM


Nodules can move up to 3x their size during your peripheral bronchoscopy. Learn more about the importance of an accurate procedural map which accounts for respiratory movement. Dr Rutland from West Coast Lung will engage in a case-based discussion to review the tools available to mitigate and track nodule movement during peripheral bronchoscopy.

Speaker: Cedric "Jamie" Rutland M.D. West Coast Lung

Company: Olympus America, Inc

The Olympus Hybrid Bronchoscopy Solution - The Right Scope, for the Right Patient, for the Right Situation

01:30 PM - 01:50 PM


The Olympus Hybrid Bronchoscopy Solution Olympus offers one of the most comprehensive bronchoscope portfolios on the market today, with a conventional and single-use suite that can tackle almost any bronchoscopy procedure. The Olympus premium single-use bronchoscope portfolio marks another milestone in advancing technology in respiratory care. It's designed to provide convenience and workflow efficiencies with increased utility in complex procedures, making it a nice compliment to your facility's bronchoscope mix.  

Speaker: Momen Wahidi M.D., MBA Duke University Medical Center

Company: Olympus America Inc.

Guru Bar 2

Every COPD Exacerbation Matters: Improving Patient Identification Ahead of Potential Future Exacerbations

12:00 PM - 12:20 PM


Join leading expert Dr Sanjay Sethi in an interactive discussion where we will explore the clinical consequences of COPD exacerbations and the risk of future events. The session will also help to identify at-risk patients who may benefit from the reevaluation of therapy. This Guru Bar will conclude with an interactive exchange exploring your clinical questions.

Speaker: Dr. Sanjay Sethi MD Jacobs School of Medicine & Biomedical Sciences

Company: GSK

Is it Really Non-CF Bronchiectasis? Recognizing Cystic Fibrosis in Adults

01:00 PM - 01:20 PM


Although newborn screening has dramatically improved early diagnosis of cystic fibrosis, patients are still missed. This Guru Bar will review the incidence of newly diagnosed cystic fibrosis in adults, the criteria used to establish the diagnosis of cystic fibrosis in adults, and the unique aspects of the genotype and phenotype of adults with cystic fibrosis with a special emphasis on clinical manifestations that can lead to diagnosis. In addition, we will review the impact of a delayed diagnosis on long-term outcomes. For the discussion section, Dr. Polineni will review case studies of cystic fibrosis diagnosis in adults with the audience to highlight diagnostic challenges and solutions.

Speaker: Deepika Polineni MD, MPH University of Kansas

Company: Vertex Pharmaceuticals, Inc.

Guru Bar 3

Alpha-1 Antitrypsin Deficiency and A Clear Path Forward (Open to U.S. attendees only)

11:30 AM - 11:50 AM


Join us to learn about:
• The need to screen for alpha1-antitrypsin deficiency (AATD)
• Testing for AATD, test results, and management approaches
• GLASSIA®: For chronic augmentation and maintenance
therapy in adults with severe AATD with clinically evident
emphysema

Speaker: Dr. Kyle Hogarth MD, FCCP The University of Chicago Medicine Chicago, Illinois

Company: Takeda Pharmaceuticals U.S.A., Inc.

Nasal High Flow for Hypoxemic Respiratory Failure

12:30 PM - 12:50 PM


During this session we will briefly review the mechanisms of action and Clinical Practice Guidelines regarding the use of Nasal High Flow for Hypoxemic Respiratory Failure

Speaker: Chris Hutchinson PGDip BE Fisher & Paykel Healthcare

Company: Fisher & Paykel Healthcare

Focus on Type 2 Inflammation in Asthma and Eosinophilic COPD

01:30 PM - 01:50 PM


Join us as we go beyond the inflammatory cascade and break down the clinical importance of type 2 inflammation in many patients with asthma and eosinophilic COPD.  We will explore common clinical manifestations of type 2 inflammation and physiologic changes associated with symptoms.

Speaker: Monica Kraft MD University of Arizona Health Sciences

Company: Sanofi and Regeneron

Guru Bar 4

Quality of Life Living with COPD – A Statistically Significant Improvement with Humidified High Flow Therapy

12:00 PM - 12:20 PM


Humidified High Flow Therapy has historically been thought of as solely an acute application. Recently, new clinical evidence suggests that proactively implementing HHFT in chronic care can slow the clinical progression of COPD and in turn improve patient quality of life. Join this session to learn more about the outcomes seen in clinical evidence, and various opportunities for implementation.

Speaker: James Gibbons Fisher & Paykel Healthcare

Company: Fisher & Paykel Healthcare

TEZSPIRE (tezepelumab-ekko): A Clinical Overview

01:00 PM - 01:20 PM


Please join Amgen and AstraZeneca as they share a different approach that may shift your point of view. Our expert will cover the efficacy and safety data and how it may apply in clinical practice.

Speaker: Ellen Sher MD Allergy Partners of NJ, PC

Company: Amgen/AstraZeneca

Monday, May 16, 2022

Moscone Center

Guru Bar 1

Lung Transplant X-ray Velocimetry Monitoring Program

11:30 AM - 11:50 AM


Improving lung health for patients at risk and those who have undergone lung transplantation is the core mission of the Lung Transplant Foundation (LTF). The Jeff Goldstein BETTER program provides healthcare professionals with dynamic functional lung information (XV LVAS, 4DMedical) to enable decision support and help drive improved member engagement and outcomes. This partner program, dedicated to honoring the legacy of LTF founder Jeffrey R. Goldstein, is real-world evaluation of X-ray Velocimetry and provides early access to novel innovative technology with the goal to promote early identification and/or detection of changes in lung transplant patient’s lung health, including allograft dysfunction.

Speakers: Greg Mogel MD ; Amy Skiba Lung Transplant Foundation

Company: 4DMedical

Clinical Application of Functional Lung Imaging in Monitoring of Silicosis

12:30 PM - 12:50 PM


Silicosis has re-emerged as a major public health concern due to exposure to toxic silica dust resulting in lung disease and reduced quality of life. Whole lung lavage (WLL) is an experimental procedure pioneered to treat silicosis. Here we present a case illustrating treatment for progressive massive fibrosis. The patient underwent pre- and post-WLL chest CT and innovative functional lung imaging (XV LVAS, 4DMedical) to determine the efficacy of the procedure. X-ray Velocimetry (XV) is a non-invasive functional measurement of regional distribution of ventilation from fluoroscopic images during tidal breathing. We demonstrated regional improvements in respiratory function as assessed by XV imaging following WLL, while no changes were observed on serial CTs. XV technology may provide value in the assessment of lung function when monitoring disease progression and effectiveness of treatment.

Speakers: Nina Eikelis PhD (Medicine) ; Greg Mogel MD

Company: 4DMedical

The Olympus Hybrid Bronchoscopy Solution - The Right Scope, for the Right Patient, for the Right Situation

01:30 PM - 01:50 PM


The Olympus Hybrid Bronchoscopy Solution Olympus offers one of the most comprehensive bronchoscope portfolios on the market today, with a conventional and single-use bronchoscope suite that can tackle almost any bronchoscopy procedure. The Olympus premium single-use bronchoscope portfolio marks another milestone in advancing technology in respiratory care. It's designed to provide convenience and workflow efficiencies with increased utility in complex procedures, making it a nice compliment to your facility's bronchoscope mix. 

Speaker: Momen Wahidi M.D., MBA Duke University Medical Center

Company: Olympus America Inc.

Guru Bar 2

Taking control of the “forgotten ventricle” in the COVID-19 ECMO Patient (Open to U.S. attendees only)

12:00 PM - 12:20 PM


COVID-19 has brought VV ECMO into greater focus.  A traditional approach to cannulating for VV ECMO has been a “two-stick” approach.  Recent advancements in technology have opened the door for increased use of single access site dual lumen cannulae.  Let’s debate the right tool for the job.

Speaker: Akram Zaaqoq MD MedStar Washington Hospital Center

Company: LivaNova, USA

TEZSPIRE (tezepelumab-ekko): A Clinical Overview

01:00 PM - 01:20 PM


Please join Amgen and AstraZeneca as they share a different approach that may shift your point of view. Our expert will cover the efficacy and safety data and how it may apply in clinical practice.

Speaker: Kevin Murphy MD Boys Town National Research Hospital

Company: Amgen/AstraZeneca

Guru Bar 3

What’s Driving These Diseases in Your Patients? Targeting Eosinophils in Patients with Severe Eosinophilic Asthma (SEA) or Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) (Open to U.S. attendees only)

11:30 AM - 11:50 AM


Do your patients have SEA with comorbid nasal polyps? Do your patients with CRSwNP remain symptomatic? Join Dr. Katharine Woessner for a discussion about a targeted biologic treatment for patients with CRSwNP or SEA. This program will discuss clinical data including reduction in nasal polyp symptoms, surgery, and systemic steroid use in patients with CRSwNP, as well as reduction in asthma exacerbations in patients with SEA. This program will conclude with an interactive exchange exploring your clinical questions.

Speaker: Katharine Woessner MD Scripps Clinic San Diego, CA

Company: GSK

Nasal High Flow for Hypercapnic Patients

12:30 PM - 12:50 PM


During this session we will briefly review the mechanisms of action and current guidance regarding the use of Nasal High Flow for Hypercapnic Patients.

Speaker: Chris Hutchinson PGDip BE Fisher & Paykel Healthcare

Company: Fisher & Paykel Healthcare

Ventilation Heterogeneity Measured Using X-ray Velocimetry

01:30 PM - 01:50 PM


Many lung diseases are characterized by functional heterogeneity, which is difficult to detect using conventional respiratory tests. Novel functional imaging-based technique, known as X-ray Velocimetry (XV), was used for regional lung function assessments, including quantification of functional heterogeneity. The whole lung ventilation heterogeneity of healthy subjects demonstrates consistency between inspiration and expiration. Further, there is topographical variation in heterogeneity at a lobe-wise level, which is unrelated to differences in lobe volumes. Accordingly, XV is a clinically available, non-invasive technique for quantification of regional lung function assessments and to identify lobar and regional variation in lung disease.

Speakers: Andreas Fouras PhD ; Greg Mogel MD

Company: 4DMedical

Guru Bar 4

Optimize Ventilator Weaning & Decannulation – Humidified High Flow Therapy an Emerging Tool

12:00 PM - 12:20 PM


During this session you can expect to learn about the various applications of Humidified High Flow Therapy to improve outcomes in ventilator weaning. Applications discussed include: HHFT during ventilator liberation, post ventilator liberation use, as well as implementation in a chronic setting.

Speaker: James Gibbons Fisher & Paykel Healthcare

Company: Fisher & Paykel Healthcare

Closing the Gap: Diversity and Disparities in Cystic Fibrosis Diagnosis

01:00 PM - 01:20 PM


Although newborn screening has dramatically improved early diagnosis of cystic fibrosis, racial and ethnic minorities including Asian, Black and Hispanic patients are more often missed than non-Hispanic White patients. This Guru Bar will focus on  the prevalence and unique aspects of the diagnosis of cystic fibrosis in minoritized patients, with a special emphasis on clinical symptoms that indicate the need for further evaluation. For the discussion section, Dr. Polineni will review case studies of cystic fibrosis diagnosis in minoritized populations with the audience to highlight diagnostic challenges and solutions.

Speaker: Deepika Polineni MD, MPH University of Kansas

Company: Vertex Pharmaceuticals, Inc.

Tuesday, May 17, 2022

Moscone Center

Guru Bar 1

Non-invasive Functional Lung Imaging Using X-ray Velocimetry

11:30 AM - 11:50 AM


X-ray Velocimetry (XV) is a novel method of functional lung imaging that uses non-invasive imaging to measure change in volume. Fluoroscopic imaging of lung motion (15 frames/s) during inspiratory and expiratory breath cycles are acquired from standard projections compatible with X-ray Velocimetry lung ventilation analysis software (XV LVAS, 4DMedical, Australia). This session describes how non-invasive measurement of tidal volume using X-ray Velocimetry are comparable to quantified flow measurements derived using pneumotachography. XV can non-invasively quantify dynamic lung function with the potential to assess heterogeneity of ventilation across the spectrum of health and disease.

Speakers: Tamás Ötvös MD ; Sonali Bose MD, MPH

Company: 4DMedical

ELEVATE IPF Study

12:30 PM - 12:50 PM


Please join us to hear about the upcoming ELEVATE IPF Study.  ELEVATE IPF Study is a Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF).  The primary aim is to evaluate safety, tolerability and efficacy of two different doses of LYT-100 compared to pirfenidone or placebo in adults with IPF.  

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases.  For more information, visit www.puretechhealth.com.

Speaker: Paul Ford MD, PhD PureTech Health

Company: PureTech Health

Ventilation Heterogeneity as a Functional Phenotype in COPD

01:30 PM - 01:50 PM


Variations in bronchial anatomy and regional ventilation have been associated with the development of chronic respiratory diseases including COPD. It is important to assess the feasibility of utilizing a non-invasive radiographic measure of lung function among individuals with COPD and examine repeated measurement of ventilation heterogeneity in a spectrum of participants from health and disease. X-ray Velocimetry lung ventilation analysis software (XV LVAS, 4DMedical, Australia) is a non-invasive functional lung imaging procedure for examining the lobar distribution lung function. Using XV in the assessment of ventilation heterogeneity in COPD patients can demonstrate functional phenotypes. Differences in airway anatomy and regional ventilation is hypothesized to be related the pathogenesis of COPD via several mechanisms including altered mucociliary clearance, particle deposition and airway remodeling. There is a need to assess whether unique radiographic phenotypes predispose to chronic respiratory disease.

Speakers: Jason Kirkness PhD (Medicine) ; Michael G. Lester MD

Company: 4DMedical

Guru Bar 2

ILD Radiology Rounds App: HRCT in the Palm of Your Hand

12:00 PM - 12:20 PM


In this digitally enhanced Guru Bar, Dr. Joseph Mammarappallil, a cardiothoracic radiologist from Duke University Medical Center, will explore the Rad Rounds – UIP to IPF app. Dr. Mammarappallil will review the radiology content contained in the app and “Test Your Knowledge” cases with the audience, with the goal of improving recognition of interstitial lung disease on HRCT scans. This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

Speaker: Joseph G. Mammarappallil MD, PhD Duke University Medical Center, Durham, NC

Company: Boehringer Ingelheim Pharmaceuticals, Inc

Why and when is IL-8 inflammation important in COVID-19?

01:00 PM - 01:20 PM


During this session, the role of inflammation and IL-8 in COVID-19 pneumonia will be reviewed. Current and future treatment strategies of inflammation during SARS-CoV-2 infection will be overviewed, including the benefit of novel inhibition of IL-8.

Speakers: Michael Niederman MD New York Presbyterian/ Weill Cornell Medical Center, USA ; Alberto Papi MD University of Ferrara, Italy

Company: Dompé U.S. Inc.

Guru Bar 3

Respiratory Syncytial Virus (RSV) in Older Adults: What's the Real Risk?

11:30 AM - 11:50 AM


Every year, respiratory syncytial virus (RSV) is estimated to cause more than 177,000 hospitalizations and 14,000 deaths in older adults in the United States. Learn more about the presentation of RSV in older adult populations and the considerable medical, humanistic, and economic burden associated with it.

Speaker: Chime Nnadi MD, PhD Janssen Infectious Diseases & Vaccines

Company: Janssen Therapeutics, a Division of Janssen Products, LP

Innovative trial design: Inhaled imatinib for Pulmonary Arterial Hypertension, design of the phase 2b/3 IMPAHCT study.

12:30 PM - 12:50 PM


Innovative clinical trial designs play a key role in the ability to efficiently study rare diseases with a limited patient pool and multiple ongoing clinical studies, such as in Pulmonary Arterial Hypertension, where an urgent needs remains for new therapies.

The novel design of the ongoing phase 2b/3 Inhaled iMatinib for Pulmonary Arterial Hypertension Clinical Trial, IMPAHCT, (Study AV-101-002; NCT05036135), an operationally seamless, continuous recruitment, adaptive clinical trial will be presented with the opportunity for discussion and questions.

Speaker: Hunter Gillies MD Aerovate Therapeutics

Company: Aerovate Therapeutics

ELEVATE IPF Study

01:30 PM - 01:50 PM


Please join us to hear about the upcoming ELEVATE IPF Study.  ELEVATE IPF Study is a Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF).  The primary aim is to evaluate safety, tolerability and efficacy of two different doses of LYT-100 compared to pirfenidone or placebo in adults with IPF.  

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases.  For more information, visit www.puretechhealth.com.

Speaker: Paul Ford MD, PhD PureTech Health

Company: PureTech Health

Guru Bar 4

Unlocking the 95%: Improving Patient Access to Clinical Trials

12:00 PM - 12:20 PM


Up to 95% of patients are traditionally unreached by clinical trials. How can we reach and engage these patients?

Patients are the key source of data contributing to the success of a clinical trial and its ability to bring new treatments to market, but are often unaware of the opportunity to participate in research.

Increasing both the number of patients, as well as the diversity of those patients, who participate in trials remains a mutual challenge for drug sponsors, research organizations, and the patients themselves.

In this group discussion, we will explore the role that community physicians can play in improving clinical trial diversity, recruitment, and retention.

Speakers: Chelsea Colby MBA TrialSpark; Arline Tejada TrialSpark

Company: TrialSpark